Screener
Syndax Pharmaceuticals SNDX Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other interest expense | — | (2) |
| Interest income | 3,561 | 7,183 |
| Other expense | (186) | (221) |
| Total other (expense) income, net | (8,471) | (1,089) |
| Net loss | $(42,673) | $(84,846) |
| Other Comprehensive loss: | ||
| Unrealized (loss) gain on marketable securities | (441) | 364 |
| Other Comprehensive loss | (43,114) | (84,482) |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's other income (expense)?
- Syndax Pharmaceuticals (SNDX) reported other income (expense) of -$8.47M in Q1 2026.
- How has Syndax Pharmaceuticals's other income (expense) changed year-over-year?
- Syndax Pharmaceuticals's other income (expense) decreased by 677.9% year-over-year, from -$1.09M to -$8.47M.
- What is the long-term trend for Syndax Pharmaceuticals's other income (expense)?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's other income (expense) has grown at a 61.3% compound annual growth rate (CAGR), from $2.94M to -$12.34M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Syndax Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude